

Experiment Number: 99009 - 01
Test Type: 90-DAY
Route: GAVAGE
Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin
CAS Number: 607-91-0

Date Report Requested: 11/14/2016
Time Report Requested: 11:35:41
First Dose M/F: 01/20/09 / 01/21/09
Lab: BAT

F1_RD_Rev.2

NTP Study Number: C99009
Lock Date: 04/22/2010
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.3_002
PWG Approval Date: 05/22/2012

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS MALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
Disposition Summary						
Animals Initially In Study	10	10	10	10	10	10
Early Deaths						
Survivors						
Terminal Sacrifice	10	10	10	10	10	10
Animals Examined Microscopically	10	10	10	10	10	10
ALIMENTARY SYSTEM						
Esophagus	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic						1 (10%)
Intestine Large, Cecum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Colon	(10)	(0)	(0)	(0)	(0)	(10)
Parasite Metazoan						1 (10%)
Intestine Large, Rectum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Duodenum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Ileum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Jejunum	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(10)	(10)
Fatty Change					10 (100%)	10 (100%)
Hepatodiaphragmatic Nodule	1 (10%)	1 (10%)	1 (10%)	3 (30%)		1 (10%)
Mixed Cell Focus						1 (10%)
Centrilobular, Hepatocyte, Hypertrophy					10 (100%)	10 (100%)
Hepatocyte, Necrosis						8 (80%)
Pancreas	(10)	(0)	(0)	(0)	(0)	(10)
Salivary Glands	(10)	(0)	(0)	(0)	(10)	(10)
Submandibular Gland, Depletion Secretory						7 (70%)
Stomach, Forestomach	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, Glandular	(10)	(10)	(10)	(10)	(10)	(10)
Epithelium, Atrophy						10 (100%)
Epithelium, Hyperplasia						10 (100%)
CARDIOVASCULAR SYSTEM						

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS MALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
Blood Vessel	(10)	(0)	(0)	(0)	(0)	(10)
Heart	(10)	(0)	(0)	(0)	(0)	(10)
Cardiomyopathy	10 (100%)					4 (40%)

ENDOCRINE SYSTEM

Adrenal Cortex	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal Medulla	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid Gland	(7)	(0)	(0)	(0)	(0)	(10)
Pituitary Gland	(10)	(0)	(0)	(0)	(0)	(10)
Thyroid Gland	(10)	(0)	(0)	(0)	(0)	(10)

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Epididymis	(10)	(10)	(10)	(10)	(10)	(10)
Exfoliated Germ Cell	1 (10%)	3 (30%)	1 (10%)	2 (20%)	4 (40%)	10 (100%)
Preputial Gland	(10)	(0)	(0)	(0)	(0)	(10)
Prostate	(10)	(0)	(0)	(0)	(0)	(10)
Seminal Vesicle	(10)	(0)	(0)	(0)	(0)	(10)
Testes	(10)	(10)	(10)	(10)	(10)	(10)
Elongated Spermatid, Retention	5 (50%)	3 (30%)		1 (10%)	6 (60%)	10 (100%)
Germinal Epithelium, Degeneration	5 (50%)	5 (50%)	3 (30%)	6 (60%)	8 (80%)	10 (100%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(10)	(0)	(0)	(0)	(0)	(10)
Lymph Node, Mandibular	(10)	(0)	(0)	(0)	(0)	(10)
Lymph Node, Mesenteric	(10)	(0)	(0)	(0)	(0)	(10)
Spleen	(10)	(0)	(0)	(0)	(0)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS MALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
Thymus	(10)	(0)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM						
Mammary Gland	(10)	(0)	(0)	(0)	(0)	(10)
Skin	(10)	(1)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM						
Bone	(10)	(0)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM						
Brain	(10)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM						
Lung	(10)	(10)	(10)	(10)	(10)	(10)
Inflammation, Chronic Active	9 (90%)	10 (100%)	10 (100%)	10 (100%)	9 (90%)	9 (90%)
Metaplasia, Osseous	1 (10%)		1 (10%)			1 (10%)
Mineralization	1 (10%)					
Alveolar Epithelium, Hyperplasia		1 (10%)				
Alveolus, Infiltration Cellular, Histiocyte	9 (90%)	6 (60%)	8 (80%)	9 (90%)	10 (100%)	8 (80%)
Pleura, Inflammation, Chronic						1 (10%)
Nose	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic Active						1 (10%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	2 (20%)					2 (20%)
Olfactory Epithelium, Degeneration	1 (10%)					
Olfactory Epithelium, Metaplasia, Squamous	1 (10%)					
Respiratory Epithelium, Accumulation, Hyaline Droplet	1 (10%)					2 (20%)
Trachea	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic						1 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS MALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
<hr/>						
SPECIAL SENSES SYSTEM						
Eye	(10)	(0)	(0)	(0)	(0)	(10)
Harderian Gland	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic	1 (10%)					
<hr/>						
URINARY SYSTEM						
Kidney	(10)	(10)	(10)	(10)	(10)	(10)
Mineralization	9 (90%)	7 (70%)	7 (70%)	9 (90%)	10 (100%)	10 (100%)
Nephropathy	10 (100%)	10 (100%)	9 (90%)	10 (100%)	10 (100%)	10 (100%)
Renal Tubule, Accumulation, Hyaline Droplet					10 (100%)	10 (100%)
Renal Tubule, Dilatation						1 (10%)
Urinary Bladder	(10)	(0)	(0)	(0)	(0)	(10)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS FEMALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
-------------------------	---------	----------	----------	-----------	-----------	-----------

Disposition Summary

Animals Initially In Study	10	10	10	10	10	10
Early Deaths						
Moribund Sacrifice						1
Natural Death						2
Survivors						
Terminal Sacrifice	10	10	10	10	10	7
Animals Examined Microscopically	10	10	10	10	10	10

ALIMENTARY SYSTEM

Esophagus	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Cecum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Colon	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Rectum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Duodenum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Ileum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Jejunum	(10)	(0)	(0)	(0)	(0)	(8)
Liver	(10)	(10)	(10)	(10)	(10)	(10)
Fatty Change					1 (10%)	10 (100%)
Hepatodiaphragmatic Nodule	1 (10%)	3 (30%)	1 (10%)	2 (20%)	1 (10%)	1 (10%)
Inflammation, Granulomatous	6 (60%)	6 (60%)	8 (80%)	5 (50%)	10 (100%)	
Necrosis						1 (10%)
Centrilobular, Hepatocyte, Hypertrophy					10 (100%)	7 (70%)
Hepatocyte, Necrosis						6 (60%)
Pancreas	(10)	(0)	(0)	(0)	(0)	(10)
Salivary Glands	(10)	(0)	(0)	(10)	(10)	(10)
Submandibular Gland, Depletion Secretory					10 (100%)	7 (70%)
Stomach, Forestomach	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Acute						1 (10%)
Stomach, Glandular	(10)	(10)	(10)	(10)	(10)	(10)
Epithelium, Atrophy					5 (50%)	7 (70%)
Epithelium, Hyperplasia						7 (70%)
Epithelium, Necrosis						2 (20%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS FEMALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
CARDIOVASCULAR SYSTEM						
Blood Vessel	(10)	(0)	(0)	(0)	(0)	(10)
Heart	(10)	(0)	(0)	(0)	(0)	(10)
Cardiomyopathy	6 (60%)					4 (40%)
ENDOCRINE SYSTEM						
Adrenal Cortex	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal Medulla	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid Gland	(10)	(0)	(0)	(0)	(0)	(8)
Pituitary Gland	(10)	(0)	(0)	(0)	(0)	(10)
Thyroid Gland	(10)	(0)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Clitoral Gland	(10)	(0)	(0)	(0)	(0)	(10)
Ovary	(10)	(1)	(2)	(1)	(1)	(10)
Cyst		1 (100%)	2 (100%)	1 (100%)	1 (100%)	
Uterus	(10)	(0)	(0)	(0)	(0)	(10)
HEMATOPOIETIC SYSTEM						
Bone Marrow	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Granulomatous	2 (20%)					
Lymph Node, Mandibular	(10)	(0)	(0)	(0)	(0)	(10)
Lymph Node, Mesenteric	(10)	(0)	(0)	(0)	(0)	(10)
Spleen	(10)	(0)	(0)	(0)	(0)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS FEMALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
Thymus	(10)	(0)	(0)	(0)	(0)	(10)
Cortex, Depletion Lymphoid						1 (10%)
Cortex, Necrosis, Lymphoid						3 (30%)
INTEGUMENTARY SYSTEM						
Mammary Gland	(10)	(0)	(0)	(0)	(0)	(10)
Skin	(10)	(0)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM						
Bone	(10)	(0)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM						
Brain	(10)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM						
Lung	(10)	(10)	(10)	(10)	(10)	(10)
Foreign Body			1 (10%)			
Inflammation, Chronic Active	2 (20%)	6 (60%)	7 (70%)	7 (70%)	10 (100%)	5 (50%)
Mineralization	1 (10%)					
Alveolus, Infiltration Cellular, Histiocyte	2 (20%)	5 (50%)	8 (80%)	8 (80%)	9 (90%)	7 (70%)
Nose	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation	1 (10%)					
Inflammation, Chronic	1 (10%)					
Olfactory Epithelium, Accumulation, Hyaline Droplet	6 (60%)					2 (20%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	3 (30%)					2 (20%)
Trachea	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation	1 (10%)					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99009 - 01

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Myristicin

CAS Number: 607-91-0

Date Report Requested: 11/14/2016

Time Report Requested: 11:35:41

First Dose M/F: 01/20/09 / 01/21/09

Lab: BAT

FISCHER 344 RATS FEMALE	0 mg/kg	10 mg/kg	30 mg/kg	100 mg/kg	300 mg/kg	600 mg/kg
SPECIAL SENSES SYSTEM						
Eye	(10)	(1)	(0)	(0)	(0)	(10)
Hemorrhage		1 (100%)				
Anterior Chamber, Exudate						1 (10%)
Cornea, Inflammation, Acute						1 (10%)
Posterior Chamber, Exudate						1 (10%)
Retina, Degeneration						1 (10%)
Harderian Gland	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic	1 (10%)					
Acinus, Metaplasia						1 (10%)
<hr/>						
URINARY SYSTEM						
Kidney	(10)	(0)	(0)	(0)	(0)	(10)
Mineralization	8 (80%)					8 (80%)
Nephropathy	3 (30%)					2 (20%)
Renal Tubule, Dilatation	1 (10%)					
Urinary Bladder	(10)	(0)	(0)	(0)	(0)	(10)

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion